Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind comparison of nephrotoxicity after gadodiamide (Omniscan) vs gadopentetate dimeglumine (Magnevist) in MR angiography
2005-004207-11Phase 4Terminated
- Sponsor
- Skåne University Hospital
- Start
- Nov 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Omniscan arm with Magnevist arm (2 arms). Primary endpoint: Peak increase in serum creatinine. Started Nov 2005; status: terminated.
02
Drugs
gadodiamidegadopentetate dimeglumine
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2005-004207-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004207-11.